Table 1. Drug resistance and compensatory mutations in poly-resistant isolates a .
| Isolate | Patient | INH | PinhA | RIF | RpoB | RpoA | RpoC | PZA | pncA | EMB | STR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M02010519 | P052 | R | -15 c > t | R | V170n b | . | . | S | . | S | S |
| M04001224 | P052 | R | -15 c > t | R | V170F | . | W484G | S | . | S | S |
| M04000819 | P153 | R | -15 c > t | R | V170F | T187A | . | S | . | S | S |
| M05010916 | P224 | R | -15 c > t | R | V170L | . | N698S | S | . | S | S |
| M05011996 | P230 | R | -15 c > t | R | V170F+T399I | . | . | R | 170 a > at | S | S |
| M08003689 | P316 | R | -15 c > t | R | V170F | . | G571R | S | . | S | S |
| H121920020 | P316 | R | -15 c > t | R | V170F | . | G571R | S | . | S | S |
| H101480093 | P360 | R | -15 c > t | R | V170F | . | G571R | S | . | S | S |
| H102780066 | P367 | R | -15 c > t | R | V170F | . | G571R | S | . | S | S |
| H111560023 | P367 | R | -15 c > t | R | V170F | . | G571R | S | . | S | S |
| H112020004 | P383 | R | -15 c > t | R | V170F | . | G571R | S | . | S | S |
| M01004483 | P060 | R | -15 c > t | R | H445R | . | . | S | . | S | S |
| M07011246 | P251 | R | -15 c > t | R | H445D | . | . | S | . | S | S |
| M10010295 | P356 | nd | -15 c > t | nd | H445N | . | . | nd | . | nd | nd |
a Phenotypic resistance (R) or sensitivity (S) to isoniazid (INH), rifampicin (RIF), pyrazinamide (PZA), ethambutol (EMB), and streptomycin (STR), with associated genotypes in the mabA-inhA operon promoter (PinhA, INH), RpoB (RIF), and PncA (PZA). Substitutions in RpoA or RpoC and RpoB T399I are putative compensatory mutations. Nucleotides are given in lower case and amino acids in upper case. nd, not determined.
b Heterogeneous allele (see Acquisition of Drug Resistance and Compensatory Mutations).